{"nctId":"NCT00531817","briefTitle":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","startDateStruct":{"date":"2007-10"},"conditions":["Rheumatoid Arthritis"],"count":619,"armGroups":[{"label":"Tocilizumab 8 mg/kg + DMARDs","type":"EXPERIMENTAL","interventionNames":["Drug: Tocilizumab","Drug: Permitted DMARDs"]},{"label":"Placebo + DMARDs","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Permitted DMARDs"]}],"interventions":[{"name":"Tocilizumab","otherNames":["Actemra","RoActemra"]},{"name":"Placebo","otherNames":[]},{"name":"Permitted DMARDs","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients, ≥18 years of age\n* Active rheumatoid arthritis of \\>6 months duration\n* Received permitted DMARDs each at a stable dose for at least 7 weeks prior to baseline\n\nExclusion Criteria:\n\n* Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis\n* Major surgery within 8 weeks prior to screening or planned within 6 months following randomization\n* Unsuccessful treatment with a biologic agent, including an anti-TNF agent\n* Previous treatment with tocilizumab","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Percentage of Patients With an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20, ACR50, ACR70) From Baseline at Weeks 4, 8, 12, 16, 20, and 24","description":"Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.2","spread":null},{"groupId":"OG001","value":"17.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null},{"groupId":"OG001","value":"14.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","spread":null},{"groupId":"OG001","value":"15.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24","description":"Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C-reactive protein or, if missing, erythrocyte sedimentation rate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.1","spread":null},{"groupId":"OG001","value":"11.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 4, 8, 12, 16, 20, and 24","description":"DAS28 was calculated using the following formula: 0.56 × sqrt(TJC) + 0.28 × sqrt(SJC) + 0.70 × ln(ESR) + 0.014 × GH, where TJC = tender joint count on 28 joints, SJC = swollen joint count on 28 joints, ESR = erythrocyte sedimentation rate at the current visit (mm/hr), and GH = general health, ie, the patient's global assessment of disease activity (DA) in the previous 24 hours on a 100 mm visual analog scale (no DA to maximum DA). The DAS28 score ranges from 0 to 10, with higher scores indicating more rheumatoid arthritis. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.77","spread":"1.264"},{"groupId":"OG001","value":"-0.45","spread":"1.065"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.32","spread":"1.454"},{"groupId":"OG001","value":"-0.72","spread":"1.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.63","spread":"1.433"},{"groupId":"OG001","value":"-0.97","spread":"1.242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.63","spread":"1.605"},{"groupId":"OG001","value":"-0.93","spread":"1.289"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.14","spread":"1.535"},{"groupId":"OG001","value":"-1.36","spread":"1.353"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.18","spread":"1.526"},{"groupId":"OG001","value":"-1.23","spread":"1.273"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With European League Against Rheumatism (EULAR) Good, Moderate, or no Response at Weeks 4, 8, 12, 16, 20, and 24","description":"Change of the DAS28 score from baseline was used to determine the EULAR responses of good, moderate, or no response. For a post-baseline score ≤ 3.2, a change from baseline of \\< -1.2 was a good response, \\< -0.6 to ≥ -1.2 was a moderate response, and ≥ -0.6 was no response. For a post-baseline score \\> 3.2 to ≤ 5.1, a change from baseline of \\< -0.6 was a moderate response and ≥ -0.6 was no response. For a post-baseline score \\> 5.1, a change from baseline \\< -1.2 was a moderate response and ≥ -1.2 was no response. A good response could not be achieved for post-baseline scores \\> 3.2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.5","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null},{"groupId":"OG001","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null},{"groupId":"OG001","value":"35.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"36.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"28.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"27.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"74.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"63.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":null},{"groupId":"OG001","value":"58.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"58.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.9","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"66.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Routine Assessment Patient Index Data (RAPID) Score at Weeks 4, 8, 12, 16, 20, and 24","description":"Derived from the Multidimensional Health Assessment Questionnaire (MDHAQ), the RAPID includes 3 domains that assess disease activity in rheumatoid arthritis: A physical function score (MDHAQ items 1a-j), a pain visual analog scale score (VAS, item 2 in the MDHAQ), and a global assessment of disease activity VAS score (item 6 in the MDHAQ). Each domain is scored on a scale of 0-10. The RAPID score is the sum of the 3 domain scores divided by 3 resulting in a total score on a scale of 0-10. Higher scores indicate more disease activity and a negative change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.28","spread":"1.921"},{"groupId":"OG001","value":"-0.50","spread":"1.666"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.70","spread":"2.087"},{"groupId":"OG001","value":"-0.73","spread":"1.868"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.89","spread":"2.244"},{"groupId":"OG001","value":"-0.99","spread":"1.971"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.84","spread":"2.286"},{"groupId":"OG001","value":"-0.86","spread":"2.104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"2.212"},{"groupId":"OG001","value":"-1.51","spread":"2.213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":"2.294"},{"groupId":"OG001","value":"-1.29","spread":"2.362"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in 12-Item Short Form Health Survey v2 (SF-12) Scores at Weeks 4, 8, 12, 16, 20, and 24","description":"The SF-12 is a self-report measure of general health status with 1 or 2 items for each of 8 domains: Physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Two component summaries, physical (PCS-12) and mental (MCS-12) were calculated using norm-based scoring, resulting in means of 50 and standard deviations of 10 in the 1998 general United States population. Higher scores represent better health and a positive change from baseline represents improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.14","spread":"8.125"},{"groupId":"OG001","value":"1.35","spread":"7.501"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.79","spread":"8.862"},{"groupId":"OG001","value":"1.95","spread":"7.523"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.17","spread":"9.250"},{"groupId":"OG001","value":"2.67","spread":"8.098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","spread":"9.278"},{"groupId":"OG001","value":"2.40","spread":"8.967"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.43","spread":"9.563"},{"groupId":"OG001","value":"4.76","spread":"8.855"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.83","spread":"9.931"},{"groupId":"OG001","value":"3.57","spread":"9.116"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":"10.209"},{"groupId":"OG001","value":"1.42","spread":"9.379"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.53","spread":"10.719"},{"groupId":"OG001","value":"2.18","spread":"10.019"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.29","spread":"11.021"},{"groupId":"OG001","value":"2.59","spread":"10.848"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.26","spread":"10.845"},{"groupId":"OG001","value":"2.23","spread":"10.453"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.33","spread":"11.503"},{"groupId":"OG001","value":"3.29","spread":"10.760"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.76","spread":"12.284"},{"groupId":"OG001","value":"3.39","spread":"10.150"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 4, 8, 12, 16, 20, and 24","description":"The FACIT-F is a 13-item patient self-report questionnaire that assesses fatigue over the previous 7 days by scoring each item on a 5-point scale (0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much). An overall FACIT-F score was obtained by summing the scores of all 13 items. The overall score ranged from 0 to 52. A lower score indicates less fatigue. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.93","spread":"8.786"},{"groupId":"OG001","value":"3.06","spread":"8.011"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.65","spread":"10.039"},{"groupId":"OG001","value":"3.85","spread":"8.598"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.63","spread":"10.504"},{"groupId":"OG001","value":"3.91","spread":"10.081"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.54","spread":"10.876"},{"groupId":"OG001","value":"3.62","spread":"10.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.52","spread":"11.147"},{"groupId":"OG001","value":"6.24","spread":"11.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.43","spread":"11.513"},{"groupId":"OG001","value":"5.89","spread":"11.316"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in the Medical Outcomes Study (MOS) Sleep Scale Score at Weeks 4, 8, 12, 16, 20, and 24","description":"The MOS Sleep Scale is a 12-item patient self-report instrument that assesses the quality and quantity of sleep over the previous 4 weeks. A sleep problems index (SLP9) was generated using 9 of the 12 items (1, 3, 4, 5, 6, 7, 8, 9, 12). Each item was normalized so that the lowest and highest possible scores were set to 0 and 100, respectively. The SLP9 score is the average of the recoded 9 items. The SLP9 score ranged from 0 to 100. Higher scores represent greater sleep problems. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.68","spread":"14.334"},{"groupId":"OG001","value":"-3.87","spread":"14.892"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.05","spread":"14.384"},{"groupId":"OG001","value":"-6.77","spread":"17.256"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.27","spread":"16.824"},{"groupId":"OG001","value":"-4.80","spread":"18.242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.65","spread":"17.117"},{"groupId":"OG001","value":"-5.42","spread":"19.433"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.31","spread":"17.991"},{"groupId":"OG001","value":"-10.89","spread":"20.364"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.46","spread":"19.167"},{"groupId":"OG001","value":"-10.11","spread":"17.352"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Individual Components of the Routine Assessment Patient Index Data (RAPID) at Each Day During the First 7 Days of Treatment","description":"Derived from the Multidimensional Health Assessment Questionnaire (MDHAQ), the RAPID includes 3 domains that assess disease activity in rheumatoid arthritis: A physical function score (0-10), a pain visual analog scale score (VAS, 0-100), and a global assessment of disease activity VAS score (0-100). Each domain was assessed with the Patient Take Home Form (PTHF). Higher scores indicate more disease activity. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"1.203"},{"groupId":"OG001","value":"-0.22","spread":"1.092"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"1.307"},{"groupId":"OG001","value":"-0.19","spread":"1.197"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.46","spread":"1.376"},{"groupId":"OG001","value":"-0.09","spread":"1.254"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"1.490"},{"groupId":"OG001","value":"-0.15","spread":"1.342"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"1.499"},{"groupId":"OG001","value":"-0.27","spread":"1.316"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"1.474"},{"groupId":"OG001","value":"-0.23","spread":"1.356"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"1.518"},{"groupId":"OG001","value":"-0.33","spread":"1.315"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.50","spread":"19.636"},{"groupId":"OG001","value":"-7.76","spread":"18.498"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.68","spread":"21.439"},{"groupId":"OG001","value":"-8.79","spread":"19.053"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.60","spread":"22.387"},{"groupId":"OG001","value":"-7.87","spread":"21.506"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.22","spread":"23.202"},{"groupId":"OG001","value":"-8.46","spread":"21.637"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.53","spread":"23.915"},{"groupId":"OG001","value":"-8.47","spread":"21.536"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.33","spread":"24.608"},{"groupId":"OG001","value":"-7.98","spread":"22.056"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.68","spread":"24.881"},{"groupId":"OG001","value":"-8.51","spread":"21.148"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.44","spread":"19.690"},{"groupId":"OG001","value":"-1.32","spread":"19.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.87","spread":"21.574"},{"groupId":"OG001","value":"-2.54","spread":"19.562"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.99","spread":"22.090"},{"groupId":"OG001","value":"-2.19","spread":"21.105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.72","spread":"22.821"},{"groupId":"OG001","value":"-2.31","spread":"21.131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.54","spread":"23.256"},{"groupId":"OG001","value":"-2.93","spread":"22.111"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.90","spread":"24.409"},{"groupId":"OG001","value":"-3.20","spread":"21.936"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.54","spread":"23.836"},{"groupId":"OG001","value":"-3.50","spread":"21.654"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score (ACR20, ACR50, ACR70) From Baseline at Day 7","description":"Improvement must be seen in tender and swollen joint counts and in at least 3 of the following 5 parameters. Patient and physician assessment of patient disease activity (DA) in previous 24 hours on a visual analog scale (VAS, no DA to maximum DA); patient assessment of pain in previous 24 hours on a VAS (none to unbearable); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and C reactive protein or, if missing, erythrocyte sedimentation rate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in C-reactive Protein (CRP) at Days 3 and 7","description":"Serum concentration of CRP (high-sensitivity CRP \\[hsCRP\\] test) was analyzed by a central laboratory.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"2.391"},{"groupId":"OG001","value":"-0.52","spread":"1.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.69","spread":"2.854"},{"groupId":"OG001","value":"-0.31","spread":"1.261"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79,"n":409},"commonTop":["Upper Respiratory Tract Infection","Urinary Tract Infection","Sinusitis","Diarrhoea","Bronchitis"]}}}